The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer.

ABSTRACT:

Background

Skeletal muscle mass (SMM) loss is common in metastatic colorectal cancer (mCRC) patients and associated with poor clinical outcomes, including increased treatment-related toxicities and reduced survival. Muscle loss may contribute to reduced health-related quality of life (HRQoL), including fatigue. Our aim was to study associations between changes in SMM and concomitant changes in patient-reported HRQoL.

Methods

This was a secondary analysis of mCRC patients in the CAIRO3 randomized clinical trial who were-after initial treatment-randomized between maintenance treatment with capecitabine plus bevacizumab (CAP-B) and observation until first disease progression (PD1). Included patients had computed tomography images for SMM quantification, together with HRQoL asse

SUBMITTER: Derksen JWG 

PROVIDER: S-EPMC7432557 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature